4.7 Article

Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2018.00608

Keywords

Parkinson's disease; insulin-like growth factor-1; connectometry; diffusion tensor imaging; synuclein; amyloid; tau; dopamine

Funding

  1. Michael J. Fox Foundation for Parkinson's Research
  2. W. Garfield Weston Foundation
  3. Alzheimer's Association
  4. Canadian Institutes for Health Research
  5. Natural Sciences and Engineering Research Council of Canada
  6. AbbVie
  7. Bristol-Myers Squibb
  8. Covance
  9. GE Healthcare
  10. GlaxoSmithKline (GSK)
  11. Eli Lilly and Company
  12. Lundbeck
  13. Meso Scale Discovery (MSD)
  14. Pfizer
  15. Piramal Imaging
  16. Roche
  17. Servier
  18. UCB
  19. Michael J. Fox Foundation for Parkinsons Research
  20. Avid Radiopharmaceuticals
  21. Biogen
  22. Genentech
  23. Merck

Ask authors/readers for more resources

Background: Growing evidence shows that impaired signaling of Insulin-like Growth Factor-1 (IGF-1) is associated with neurodegenerative disorders, such as Parkinson's disease (PD). However, there is still controversy regarding its proinflammatory or neuroprotective function. In an attempt to elucidate the contribution of IGF-1 in PD, we aimed to discover the relation between serum IGF-1 levels in drug-naive early PD patients and cerebrospinal fluid (CSF) biomarkers as well as microstructural changes in brain white matter. Methods: The association between quartiles of serum IGF-1 levels and CSF biomarkers (alpha-synuclein, dopamine, amyloid-beta(1-42), total tau, and phosphorylated tau) was investigated using adjusted regression models in 404 drug-naive early PD patients with only mild motor manifestations and 188 age- and sex-matched healthy controls (HC) enrolled in the Parkinson's Progression Markers Initiative (PPMI). By using region of interest analysis and connectometry approach, we tracked the white matter microstructural integrity and diffusivity patterns in a subgroup of study participants with available diffusion MRI data to investigate the association between subcomponents of neural pathways with serum IGF-1 levels. Results: PD patients had higher levels of IGF-1 compared to HC, although not statistically significant (mean difference: 3.60, P = 0.44). However, after adjustment for possible confounders and correction for False Discovery Rate (FDR), IGF-1 was negatively correlated with CSF alpha-synuclein, total and phosphorylated tau levels only in PD subjects. The imaging analysis proved a significant negative correlation (FDR corrected P-value = 0.013) between continuous levels of serum IGF-1 in patients with PD and the connectivity, but not integrity, in following fibers while controlling for age, sex, body mass index, depressive symptoms, education years, cognitive status and disease duration: middle cerebellar peduncle, cingulum, genu and splenium of the corpus callosum. No significant association was found between brain white matter microstructral measures or CSF markers of healthy controls and levels of IGF-1. Conclusion: Altered connectivity in specific white matter structures, mainly involved in cognitive and motor deterioration, in association with higher serum IGF-1 levels might propose IGF-1 as a potential associate of worse outcome in response to higher burden of alpha-synucleinopathy and tauopathy in PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available